Santen Pharmaceutical Co (STU:SZD) E10: €0.37 (As of Mar. 2026)


STU:SZD Santen Pharmaceutical Co Ltd STU:SZD
84 GF Score
Price €11.50
GF Value €9.06
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Santen Pharmaceutical Co E10?

Santen Pharmaceutical Co STU:SZD -0.86% 84 E10 is €0.37 as of Mar. 2026. GuruFocus rates STU:SZD with a GF Score™ of 84/100 and a GF Value™ of €9.06 (Modestly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Santen Pharmaceutical Co's adjusted earnings per share data for the three months ended in Mar. 2026 was €0.260. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.37 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Santen Pharmaceutical Co's average E10 Growth Rate was -3.30% per year. During the past 3 years, the average E10 Growth Rate was 4.10% per year. During the past 5 years, the average E10 Growth Rate was 1.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Santen Pharmaceutical Co was 4.10% per year. The lowest was -3.20% per year. And the median was 1.25% per year.

As of today (2026-07-01), Santen Pharmaceutical Co's current stock price is €11.50. Santen Pharmaceutical Co's E10 for the quarter that ended in Mar. 2026 was €0.37. Santen Pharmaceutical Co's Shiller PE Ratio of today is 31.08.

During the past 13 years, the highest Shiller PE Ratio of Santen Pharmaceutical Co was 34.50. The lowest was 14.41. And the median was 25.36.


Santen Pharmaceutical Co  (STU:SZD) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Santen Pharmaceutical Co's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=11.50/0.37
=31.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Santen Pharmaceutical Co was 34.50. The lowest was 14.41. And the median was 25.36.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Santen Pharmaceutical Co E10 Related Terms


Santen Pharmaceutical Co E10 Historical Data

* Premium members only.

The historical data trend for Santen Pharmaceutical Co's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santen Pharmaceutical Co E10 Chart

Santen Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.48 0.40 0.37 0.42 0.37

Santen Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.40 0.35 0.34 0.37

STU:SZD vs LLY, JNJ, ABBV: E10 Comparison

For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santen Pharmaceutical Co Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Santen Pharmaceutical Co's Shiller PE Ratio falls into.


STU:SZD
84GF Score
Santen Pharmaceutical Co Ltd STU:SZD
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santen Pharmaceutical Co E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Santen Pharmaceutical Co's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.26/112.7000*112.7000
=0.260

Current CPI (Mar. 2026) = 112.7000.

Santen Pharmaceutical Co Quarterly Data

per share eps CPI Adj_EPS
201606 0.149 98.100 0.171
201609 0.109 98.000 0.125
201612 0.093 98.400 0.107
201703 0.093 98.100 0.107
201706 0.177 98.500 0.203
201709 0.116 98.800 0.132
201712 0.221 99.400 0.251
201803 0.148 99.200 0.168
201806 0.131 99.200 0.149
201809 0.141 99.900 0.159
201812 0.173 99.700 0.196
201903 0.169 99.700 0.191
201906 0.131 99.800 0.148
201909 0.142 100.100 0.160
201912 0.147 100.500 0.165
202003 0.070 100.300 0.079
202006 0.128 99.900 0.144
202009 0.153 99.900 0.173
202012 0.142 99.300 0.161
202103 -0.226 99.900 -0.255
202106 0.138 99.500 0.156
202109 0.134 100.100 0.151
202112 0.098 100.100 0.110
202203 0.150 101.100 0.167
202206 0.118 101.800 0.131
202209 -0.533 103.100 -0.583
202212 0.108 104.100 0.117
202303 0.018 104.400 0.019
202306 0.182 105.200 0.195
202309 0.155 106.200 0.164
202312 0.132 106.800 0.139
202403 0.002 107.200 0.002
202406 0.174 108.200 0.181
202409 0.146 108.900 0.151
202412 0.157 110.700 0.160
202503 0.159 111.100 0.161
202506 0.104 111.700 0.105
202509 0.141 112.000 0.142
202512 0.133 113.000 0.133
202603 0.260 112.700 0.260

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €0.37 mean?
Santen Pharmaceutical Co (STU:SZD) has a E10 of €0.37 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Santen Pharmaceutical Co and its competitors.
Is Santen Pharmaceutical Co's E10 too high?
Santen Pharmaceutical Co's current E10 is €0.37. Overall, Santen Pharmaceutical Co has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's E10 compare to LLY and JNJ?
Santen Pharmaceutical Co's E10 of €0.37 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Santen Pharmaceutical Co and its competitors. Santen Pharmaceutical Co's current E10 is €0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (STU:SZD) is currently considered Modestly Overvalued. The stock's GF Value™ is €9.06, compared to a current price of €11.50 — trading 26.9% above its estimated fair value. The current E10 is €0.37. Santen Pharmaceutical Co's overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Santen Pharmaceutical Co (STU:SZD), the current E10 is €0.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santen Pharmaceutical Co (STU:SZD) Overvalued in 2026?

Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued. The current stock price of €11.50 is trading 26.9% above its estimated GF Value™ of €9.06. GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for STU:SZD:

  • E10: €0.37
  • GF Value™: €9.06 vs. price of €11.50 (26.9% above fair value)
  • GF Score™: 84/100 with 6 warning signs

No single metric tells the full story. See the STU:SZD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Santen Pharmaceutical Co Business Description

Other Exchanges SNPHY:USA4536:Japan
Address 4-20 Ofukacho, Grand Front Osaka Tower A, Kita-ku, Osaka Prefecture, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
84GF Score

Get the complete analysis for STU:SZD

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.50
Price
€9.06
GF Value